z-logo
open-access-imgOpen Access
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial
Author(s) -
Elisa Nemes,
Anneke C. Hesseling,
Michèle Tameris,
Katya Mauff,
Katrina Downing,
Humphrey Mulenga,
Penelope C. Rose,
Marieke M. van der Zalm,
Sharon Mbaba,
Danelle van As,
Willem A. Hanekom,
Gerhard Walzl,
Thomas J. Scriba,
Helen McShane,
Mark Hatherill,
Charmaine Abrahams,
Deborah Abrahams,
Hadn Africa,
Veronica Baartman,
Beauty Bavuma,
Nicole Bilek,
Natasja Botes,
Yolande Brown,
Yolundi Cloete,
Margareth Damons,
Ronel De Vos,
Portia Dlakavu,
K. du Preez,
Mzwandile Erasmus,
Claudia Francis,
Hendrik Geldenhuys,
Mandy Geldenhuys,
Katriena Goedeman,
Sandra Golliath,
Angelique Mouton,
Christiaan Hopley,
Ruwijda Jansen,
Carolynne Jones,
Alana Keyser,
Benjamin M. Kagina,
Gloria Khomba,
Fazlin Kola–Cassiem,
Sandra Krüger,
Daphne Leukes,
Loyiso Louw,
Angelique Kany Kany Luabeya,
Theresa Maart,
Lebohang Makhethe,
Simbarashe Mbabwe,
Eunice Mtshamba,
Boniswa Mvinjelwa,
Lungisa Nkantsu,
Julia Noble,
Sizwe Nqweniso,
Fajwa Opperman,
Christel Petersen,
Patiswa Plaatjie,
Susan Rossouw,
Roxanne Solomoms,
Marcia Steyn,
Liticia Swanepoel,
Asma Toefy,
Heidi van Deventer,
Elma van Rooyen,
Daphne van Ster,
Bongiwe Vazana,
Ashley Veldsman,
cedo Xoyana
Publication year - 2017
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cix834
Subject(s) - vaccination , immunogenicity , tuberculosis , reactogenicity , immunology , medicine , bcg vaccine , tuberculosis vaccines , virology , immune system , mycobacterium tuberculosis , pathology
Vaccination of human immunodeficiency virus (HIV)-infected infants with bacille Calmette-Guérin (BCG) is contraindicated. HIV-exposed newborns need a new tuberculosis vaccination strategy that protects against tuberculosis early in life and avoids the potential risk of BCG disease until after HIV infection has been excluded.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom